Patient and Healthcare Provider Resource

Patient and Healthcare Providers Resource

OralChemoEdSheets.com, Patient + Healthcare Providers Resource

OralChemoEdSheets.com, the Patient and Healthcare Providers Resource

Oral Oncology Treatment Terms

Additional Resources
  • No Additional Resources

General Terms related to Oral Oncology Treatments.

 
Our Supplemental Sheet

This sheet is available to download as an Adobe PDF.

Oral Oncology Treatment Terms Supplemental Sheet

 

ORAL ONCOLOGY TREATMENT TERMS ORAL CHEMOTHERAPY EDUCATION Chemotherapy treatment cycle A course of treatment that is repeated on a regular schedule with periods of rest between. For example, treatment for 2 weeks followed by 2 weeks of rest may be considered one treatment cycle. Hormone therapy This treatment affects hormone production. Hormones can cause certain cancers to grow (e.g., prostate and breast cancer). Hormones or other medicines may be given to block the body’s natural hormones, helping to slow or stop the growth of cancer. It is also called endocrine therapy, hormonal therapy, and hormone treatment. Medication adherence The extent to which patients take medicines as ordered by healthcare providers Oral chemotherapy Treatment with medicines given by mouth to kill cancer cells or stop them from growing Targeted therapy This type of treatment uses medicine to identify and attack specific types of cancer cells. It may cause less harm to healthy cells. There are many types of targeted therapies. Some block the action of certain enzymes, proteins, or molecules involved in the growth and spread of cancer cells. Other types help the immune system kill cancer cells or deliver toxic substances directly to cancer cells and kill them. Targeted therapies may have fewer side effects than other types of cancer treatment. Bibliography National Cancer Institute. (n.d.). National Cancer Institute dictionary of cancer terms. Retrieved from https://www.cancer.gov/publications/ dictionaries/cancer terms Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353, 487–497. https://doi.org/10.1056/ NEJMra05010

Our Sponsors

  • Boehringer
  • Takeda
  • Beigene
  • Helsinn
  • Exelixis
  • Pharmacyclics